Status:
COMPLETED
Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborating Sponsors:
Triangle Pharmaceuticals
Gilead Sciences
Conditions:
HIV Infections
Antiretroviral Naive
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In 1999, when initiating antiretroviral treatment in HIV infected adults, a triple combination with protease inhibitor is recommended. Such therapy induces side effects and the number of pills may red...
Detailed Description
In 1999, when initiating antiretroviral treatment in HIV infected adults, a triple combination with protease inhibitor is recommended. Side effects of this products and the number of pills may induce ...
Eligibility Criteria
Inclusion
- HIV infection
- Antiretroviral naive
- CD4 cell count over 100/mm3
- Plasma HIV RNA load over 5,000 copies/mL
- Signed written informed consent
Exclusion
- Hepatitis B infection
- Pregnancy
- Alcool abuse
- Acute infection, past neurological or pancreatic disease, biological abnormalities
- Chemotherapy or immunotherapy
Key Trial Info
Start Date :
February 1 1999
Trial Type :
INTERVENTIONAL
End Date :
September 1 2004
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00196599
Start Date
February 1 1999
End Date
September 1 2004
Last Update
September 20 2005
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.